The Technical Analyst
Select Language :
Amgen Inc [AMGN]

Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—General

Amgen Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Amgen Inc is listed at the  Exchange

1.11% $271.91

America/New_York / 22 apr 2024 @ 16:00


FUNDAMENTALS
MarketCap: 145 722 mill
EPS: 12.48
P/E: 21.79
Earnings Date: May 02, 2024
SharesOutstanding: 535.92 mill
Avg Daily Volume: 2.94 mill
RATING 2024-04-22
S
Strong Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Buy
Return On Asset: Buy
DE: Strong Buy
P/E: Strong Buy
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 21.79 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
1.13x
Company: PE 21.79 | industry: PE 19.30
DISCOUNTED CASH FLOW VALUE
$471.87
(73.54%) $199.96
Date: 2024-04-22
Expected Trading Range (DAY)

$ 266.52 - 277.31

( +/- 1.98%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-18 Santos Esteban Sell 6 137 Common Stock
2024-03-18 Reese David M Sell 6 202 Common Stock
2024-03-18 Miller Derek Sell 475 Common Stock
2024-03-18 Khosla Rachna Sell 438 Common Stock
2024-03-18 Grygiel Nancy A. Sell 703 Common Stock
INSIDER POWER
58.90
Last 97 transactions
Buy: 472 102 | Sell: 97 922

Forecast: 16:00 - $271.69

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $271.69
Forecast 2: 16:00 - $271.69
Forecast 3: 16:00 - $271.69
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $271.91 (1.11% )
Volume 2.14 mill
Avg. Vol. 2.94 mill
% of Avg. Vol 72.79 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Amgen Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Amgen Inc

RSI

Intraday RSI14 chart for Amgen Inc

Last 10 Buy & Sell Signals For AMGN

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$293.50N/AActive
Profile picture for
            Amgen Inc

AMGN

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Last 10 Buy Signals

Date Signal @
ZBUSDApr 23 - 01:47$114.56
VRXUSDApr 23 - 01:5346.05
XAUTUSDApr 23 - 01:51$2 309.01
WEMIXUSDApr 23 - 01:48$1.900
INVUSDApr 23 - 01:4950.53
TETUSDApr 23 - 01:4421.72
DPIUSDApr 23 - 01:38$99.02
HGUSDApr 23 - 01:31$4.43
^BSESNApr 23 - 01:17PTS73 777
SAKAIUSDApr 23 - 01:303.40

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.